

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

**3DMed**

**思路迪**

**3D Medicines Inc.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1244)**

## **POSITIVE PROFIT ALERT**

This announcement is made by 3D Medicines Inc. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of The Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the Group’s unaudited management accounts for the six months ended June 30, 2023, the total revenue of the Group for the six months ended June 30, 2023 is expected to be within the range of RMB343.8 million to RMB361.4 million, representing an increase in the range of 66.1% to 74.6% from approximately RMB207.0 million for the six months ended June 30, 2022. The gross profit of the Group for the six months ended June 30, 2023 is expected to be within the range of RMB319.4 million to RMB335.8 million, representing an increase in the range of 66.1% to 74.6% from approximately RMB192.3 million for the six months ended June 30, 2022. The increase in total revenue and gross profit was mainly due to the increased revenue and the gross profit of our product, namely Envafolimab (恩維達®). The gross profit margin of the Company for the six months ended June 30, 2023 is expected to be 92.9%, which is flat compared to approximately 92.9% for the six months ended June 30, 2022.

	<b>For the six months ended June 30,</b>		
	<b>Revenue<sup>(1)</sup></b>		
	<b>2023</b>	<b>2022</b>	<b>Year-on-year</b>
	<b>(unaudited)</b>	<b>(unaudited)</b>	<b>Growth</b>
	<b>RMB million</b>	<b>RMB million</b>	
Envafolimab (恩維達®)	<u>352.6</u>	<u>207.0</u>	<u>70.3%</u>
<b>Total revenue</b>	<u><u>352.6</u></u>	<u><u>207.0</u></u>	<u><u>70.3%</u></u>

	<b>For the six months ended June 30,</b>		
	<b>Gross Profit<sup>(1)</sup></b>		
	<b>2023</b> <b>(unaudited)</b> <b>RMB million</b>	<b>2022</b> <b>(unaudited)</b> <b>RMB million</b>	<b>Year-on-year</b> <b>Growth</b>
Envafolimab (恩維達®)	<u>327.6</u>	<u>192.3</u>	<u>70.4%</u>
<b>Total gross profit</b>	<b><u>327.6</u></b>	<b><u>192.3</u></b>	<b><u>70.4%</u></b>

	<b>For the six months ended June 30,</b>		
	<b>Gross Profit Margin<sup>(2)</sup></b>		
	<b>2023</b> <b>(unaudited)</b> <b>%</b>	<b>2022</b> <b>(unaudited)</b> <b>%</b>	<b>Profit margin</b> <b>difference</b>
Envafolimab (恩維達®)	<u>92.9</u>	<u>92.9</u>	<u>0.0%</u>
<b>Total</b>	<b><u>92.9</u></b>	<b><u>92.9</u></b>	<b><u>0.0%</u></b>

(1) Revenue and gross profit for the six months ended June 30, 2023 are calculated with values at the mid-point of the expected range.

(2) Gross profit margin for the six months ended June 30, 2023 is calculated from values that are indicated in the first two tables as abovementioned.

The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2023. The operating statistics disclosed above are unaudited and based on the preliminary internal information of the Group, which may be subject to change and may differ from the figures to be disclosed in the interim results announcement of the Group for the six months ended June 30, 2023 to be published by the Company, due to various uncertainties during the process of collating such operating information. Such information has not been audited or reviewed by the auditors of the Company or the audit committee of the Board. They shall not be taken as a measure or indication of the Group's current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Group's interim results announcement for the six months ended June 30, 2023. As such, the above statistics are provided for investors' reference only. Shareholders and potential investors are advised to read carefully about the interim results announcement of the Company for the six months ended June 30, 2023, which is expected to be published by the end of August 2023 in accordance with the requirements of the Listing Rules.

**Shareholders and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors are advised to seek professional advice from professional or financial advisers.**

By order of the Board  
**3D Medicines Inc.**  
**Dr. Gong Zhaolong**  
*Chairman of the Board and Executive Director*

Hong Kong, July 7, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.*